Investigational devices are medical devices that are still undergoing evaluation and have not yet received regulatory approval or clearance from agencies like the FDA. Their use is restricted to clinical trials or research studies, and a key component of the regulatory process is the Investigational Device Exemption (IDE), which allows these devices to be used in studies to gather safety and effectiveness data.
Risk Classification: Significant vs. Nonsignificant
Before any clinical investigation of an investigational device begins, an IDE is required unless the device qualifies for an exemption. The regulatory pathway varies depending on the level of risk associated with the device:
Approval Process:
The sponsor of the study initially assesses and justifies the device’s risk level. If a device is classified as significant risk, the sponsor must submit an IDE application to the FDA before seeking IRB approval. If classified as nonsignificant risk, the protocol (including risk justification) goes directly to the IRB for a full board review. If there’s a disagreement between the sponsor and IRB on the risk level, the FDA has the final authority.
IDE Application: Key Components
For significant risk devices, the IDE application to the FDA must demonstrate that the expected benefits of the study outweigh the potential risks. Key elements of the application include:
Formatting and Submission Guidelines
To streamline the review, adhere to the following IDE submission guidelines:
Additionally, the FDA offers a checklist for IDE application cover letters, which can be found on their website, to assist in ensuring all necessary elements are included for a more efficient review.
Support for Your Quality Assurance and Regulatory Compliance Needs
Navigating the regulatory landscape for investigational devices can be challenging, especially while balancing day-to-day operations. PRP offers expert Quality Assurance and Regulatory Compliance support for medical devices and pharmaceuticals. Our team of experienced consultants across the country is ready to seamlessly integrate with your team, helping you maintain compliance and the highest quality standards. Book an appointment with our CEO, Stefanie Wichansky to discuss how we can support your compliance goals.
|